<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30334368</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>18</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1582-4934</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>17</Day>                    </PubDate>                </JournalIssue>                <Title>Journal of cellular and molecular medicine</Title>                <ISOAbbreviation>J. Cell. Mol. Med.</ISOAbbreviation>            </Journal>            <ArticleTitle>STAT1 facilitates oestrogen receptor α transcription and stimulates breast cancer cell proliferation.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1111/jcmm.13882</ELocationID>            <Abstract>                <AbstractText>Oestrogen receptor α (ERα) is overexpressed in two-thirds of all breast cancer cases and is involved in breast cancer development and progression. Although ERα -positive breast cancer can be effectively treated by endocrine therapy, endocrine resistance is an urgent clinical problem. Thus, further understanding of the underlying mechanisms involved in ERα signalling is critical in dealing with endocrine resistance in patients with breast cancer. In the present study, unbiased RNA sequence analysis was conducted between the MCF-7 and MCF-7 tamoxifen-resistant (LCC2) cell lines in order to identify differentially expressed genes. The whole transcriptomic data indicated that the JAK-STAT pathway is markedly up-regulated, particularly the ISGF3 complex. As the critical effectors, STAT1 and IRF9 were up-regulated 5- and 20-fold, respectively, in LCC2 cells. The biological experiments indicated that STAT1 is important for ERα signalling. Depletion of STAT1 or inhibition of STAT1 function significantly decreased levels of ERα protein, ERα -target gene expression and cell proliferation in both the MCF-7 and LCC2 cell lines. Chromatin immunoprecipitation revealed that ERα transcription is associated with STAT1 recruitment to the ERα promoter region, suggesting that transcriptional regulation is one mechanism by which STAT1 regulates ERα mRNA levels and ERα signalling in breast cancer cells. The present study reveals a possible endocrine-resistant mechanism by which STAT1 modulates ERα signalling and confers tamoxifen resistance. Targeting of STAT1 is a potential treatment strategy for endocrine-resistant breast cancers.</AbstractText>                <CopyrightInformation>© 2018 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley &amp; Sons Ltd and Foundation for Cellular and Molecular Medicine.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Hou</LastName>                    <ForeName>Yingxiang</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Laboratory of Molecular Oncology, Henan Collaborative Innovation Center of Molecular Diagnosis and Laboratory Medicine, School of Laboratory Medicine, Xinxiang Medical University, Xinxiang, Henan, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Henan Key Laboratory of Immunology and Targeted Drugs, Xinxiang Medical University, Xinxiang, Henan, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Institute of Lung and Molecular Therapy (ILMT), Xinxiang Medical University, Xinxiang, Henan, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Xin</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Laboratory of Molecular Oncology, Henan Collaborative Innovation Center of Molecular Diagnosis and Laboratory Medicine, School of Laboratory Medicine, Xinxiang Medical University, Xinxiang, Henan, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Henan Key Laboratory of Immunology and Targeted Drugs, Xinxiang Medical University, Xinxiang, Henan, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Institute of Lung and Molecular Therapy (ILMT), Xinxiang Medical University, Xinxiang, Henan, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Qianhua</ForeName>                    <Initials>Q</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Shandong University School of Medicine, Jinan, Shandong, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Xu</LastName>                    <ForeName>Juntao</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Rhil Rivers Technology (Beijing) Ltd, Beijing, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Cancer Genomics, LemonData Biotech (Shenzhen), Shenzhen, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yang</LastName>                    <ForeName>Huijie</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Laboratory of Molecular Oncology, Henan Collaborative Innovation Center of Molecular Diagnosis and Laboratory Medicine, School of Laboratory Medicine, Xinxiang Medical University, Xinxiang, Henan, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Henan Key Laboratory of Immunology and Targeted Drugs, Xinxiang Medical University, Xinxiang, Henan, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Institute of Lung and Molecular Therapy (ILMT), Xinxiang Medical University, Xinxiang, Henan, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Xue</LastName>                    <ForeName>Min</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Laboratory of Molecular Oncology, Henan Collaborative Innovation Center of Molecular Diagnosis and Laboratory Medicine, School of Laboratory Medicine, Xinxiang Medical University, Xinxiang, Henan, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Henan Key Laboratory of Immunology and Targeted Drugs, Xinxiang Medical University, Xinxiang, Henan, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Institute of Lung and Molecular Therapy (ILMT), Xinxiang Medical University, Xinxiang, Henan, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Niu</LastName>                    <ForeName>Gang</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Rhil Rivers Technology (Beijing) Ltd, Beijing, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Cancer Genomics, LemonData Biotech (Shenzhen), Shenzhen, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhuo</LastName>                    <ForeName>Shu</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Molecular Biology, UT Southwestern Medical Center, Dallas, Texas.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mu</LastName>                    <ForeName>Kun</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Shandong University School of Medicine, Jinan, Shandong, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wu</LastName>                    <ForeName>Gaosong</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Thyroid and Breast Surgery, Zhongnan Hospital, Wuhan University, Wuhan, Hubei, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Xiumin</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Institute of Lung and Molecular Therapy (ILMT), Xinxiang Medical University, Xinxiang, Henan, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Center for Cancer Research, Xinxiang Medical University, Xinxiang, Henan, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Hui</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Laboratory of Molecular Oncology, Henan Collaborative Innovation Center of Molecular Diagnosis and Laboratory Medicine, School of Laboratory Medicine, Xinxiang Medical University, Xinxiang, Henan, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Henan Key Laboratory of Immunology and Targeted Drugs, Xinxiang Medical University, Xinxiang, Henan, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhu</LastName>                    <ForeName>Jian</ForeName>                    <Initials>J</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0003-3596-4339</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Molecular Biology, UT Southwestern Medical Center, Dallas, Texas.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhuang</LastName>                    <ForeName>Ting</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Laboratory of Molecular Oncology, Henan Collaborative Innovation Center of Molecular Diagnosis and Laboratory Medicine, School of Laboratory Medicine, Xinxiang Medical University, Xinxiang, Henan, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Henan Key Laboratory of Immunology and Targeted Drugs, Xinxiang Medical University, Xinxiang, Henan, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Institute of Lung and Molecular Therapy (ILMT), Xinxiang Medical University, Xinxiang, Henan, China.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>8170110153</GrantID>                    <Agency>National Science Foundation for Young Scientists of China</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>15IRTSTHN025</GrantID>                    <Agency>University of Henan Province</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>17A310025</GrantID>                    <Agency>Foundation of Henan Educational Committee</Agency>                    <Country/>                </Grant>                <Grant>                    <Agency>Xinxiang Medical University</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>J Cell Mol Med</MedlineTA>            <NlmUniqueID>101083777</NlmUniqueID>            <ISSNLinking>1582-1838</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">ERα</Keyword>            <Keyword MajorTopicYN="N">STAT1</Keyword>            <Keyword MajorTopicYN="N">breast cancer</Keyword>            <Keyword MajorTopicYN="N">transcription</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>06</Month>                <Day>18</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>25</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>19</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>20</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>20</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30334368</ArticleId>            <ArticleId IdType="doi">10.1111/jcmm.13882</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>